|Audit||Nominating and Governance||Compensation|
|Dr. Glen Bradley, Ph.D.|
|Mark J. Brooks, M.B.A.|
|Brian Halak, Ph.D., B.S.E.|
Partner at Domain Associates, L.L.C.
Dr. Halek has been a member of our board of directors since 2004. Dr. Halak joined Domain Associates, L.L.C. in 2001 and has served as a Partner of Domain Associates, L.L.C. since 2006. Prior to joining Domain Associates, L.L.C., Dr. Halak served as an analyst of Advanced Technology Ventures from 2000 to 2001. From 1993 to 1995, Dr. Halak has served as an analyst of Wilkerson Group. Dr. Halak holds a Doctorate in Immunology from Thomas Jefferson University and a B.S. in Engineering from the University of Pennsylvania. Dr. Halak has served on the board of directors of more than 10 emerging companies in the life sciences industry in the past 10 years, including Dicerna Pharmaceuticals, Inc., which completed a public offering on Nasdaq in 2014,Vanda Pharmaceuticals, Inc., a public company listed on Nasdaq, and Esprit Pharma, Inc., a company that was acquired by Allergan, Inc.
|Garheng Kong, M.D., Ph.D.|
|James R. Largent|
|Peter J. Pizzo, III|